Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2025 07:00 ET | Source: Metagenomi, Inc.

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
November 26, 2025 04:00 ET | Source: Tangram Therapeutics PLC

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi...
November 17, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of...
November 10, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC

SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of...
October 16, 2025 16:32 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
October 15, 2025 09:00 ET | Source: Muscular Dystrophy Association

Agenda Announced for 2026 MDA Clinical & Scientific Conference Featuring Leading Speakers Dedicated to Groundbreaking Research and Clinical Achievements in Neuromuscular Disease

New York, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the agenda including tracks and chairs for the 2026 MDA Clinical & Scientific Conference...
October 07, 2025 06:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval and Positive Interim Clinical Data for LX2006 in FA Cardiomyopathy
October 06, 2025 01:00 ET | Source: EG 427

EG 427 Receives U.S. FDA Fast Track Designation for EG110A DNA Medicine in Neurogenic Bladder Patients

Paris, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Builds on positive top-line data from first cohort demonstrating significant reduction in urinary incontinence episodes Paris, France, October 6, 2025 –...
August 14, 2025 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
July 30, 2025 09:00 ET | Source: Muscular Dystrophy Association

Registration Now Open for the 2026 MDA Clinical & Scientific Conference Where Global Leaders in Neuromuscular Disease Research & Care Unite to Drive the Next Breakthroughs March 8-11 in Orlando, FL

New York, July 30, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), leader and innovator of the largest global gathering of the neuromuscular disease community, announced today...